Ipca Laboratories Limited (IPCALAB.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹1,967.80 (+1.51%) as of
Key statistics
- Market cap
- 499.24B
- P/E (TTM)
- 38.11
- Forward P/E
- 27.95
- EPS (TTM)
- 51.63
- Dividend yield
- 0.31%
- 52-week range
- 1,268.00 – 2,038.00
- Beta
- 0.04
- Revenue (TTM)
- 101.26B
- Profit margin
- 12.94%
- Analyst target
- ₹1,981.72
- Volume
- 32.77k
About Ipca Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 17,210
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.